S1H peptide

S1H peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

Ac-YIPKEQKYSFLQNPQT-NH2

Ac-Tyr-Ile-Pro-Lys-Glu-Gln-Lys-Tyr-Ser-Phe-Leu-Gln-Asn-Pro-Gln-Thr-NH2

16

95.19%

C₉₄H₁₄₁N₂₃O₂₇

2025.25

Synthetic

Powder

S1H is a 16-residue peptide designed as a direct sequence mimetic of the site 1 mini-helix (residues 36-51) of wild-type human growth hormone (hGH). S1H acts as an inhibitor by blocking the interaction of hGH with the human growth hormone receptor (hGHR). S1H mitigates phosphorylation of STAT5 in cells co-treated with hGH, reducing intracellular STAT5 phosphorylation levels to those of untreated controls. S1H can be used as a chemical tool to study the molecular nature of hGH–hGHR interactions.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Basu et al (2021) A novel peptide antagonist of the human growth hormone receptor. J Biol Chem. 296 100588 PMID: 33774052

Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.

Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.

Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.

In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.